Lucis, a Paris-based AI preventive health platform, has raised €17.3M ($20M) in Series A funding led by Singular, with participation from General Catalyst and Y Combinator. The company analyzes 110+ blood biomarkers across 11 body systems, integrates wearables data, and delivers clinician-reviewed personalized action plans for longevity and health optimization. The capital will expand its platform across Europe.
Europe Digital Health Funding Accelerates
The round arrives as European preventive health draws investor attention amid rising chronic disease costs and policy pushes for early detection. Lucis raised the round just four months after an $8.5M seed round, bringing total funding to $28M. Its model combines lab testing through 450+ partner labs with AI insights and wearable integrations, addressing gaps in reactive care systems.
99.9% of Users Show Out-of-Range Biomarkers
Standard care often misses early signals, with 99.9% of Lucis users having at least one out-of-range biomarker on their first test. The company has delivered over 1 million biomarker analyses to 10,000+ members. 75% of users improve three or more markers within six months without medication, per company data.
Platform Combines Labs, Wearables, and AI
Lucis membership at €490 per year provides two full assessments annually plus an app with Oura, Apple Watch, and Garmin integrations. Reports cover metabolic, hormonal, cardiovascular, and immune systems with actionable nutrition and lifestyle plans. This differs from narrower competitors focused on single areas like gut health or athletic performance.
"We’ve seen the devastating impact of late-stage diagnosis first-hand." — Maxime Berthelot, founder
"Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale." — Jeremy Uzan
Singular Leads with AI Healthtech Focus
Singular led the round, joined by tier-1 firms General Catalyst and YC. The investor mix signals conviction in AI-driven platforms that blend technical founders with clinical oversight. Lucis maintains HDS, ISO27001, and GDPR compliance with a 20-person team and medical board.
Preventive Market Expands to $703B by 2033
The preventive healthcare technologies market stands at $338.61B in 2026 and is projected to reach $703B by 2033 at 12.45% CAGR. Key drivers include aging populations, post-pandemic awareness, and regulatory tailwinds from the EU Beating Cancer Plan. Lucis positions itself as the first European preventive health OS with pan-European lab access.
Expansion Targets Spain, Germany, Italy
With deployments already in four countries, Lucis plans to enter Spain, Germany, and Italy by the end of 2026. Recent partnerships include Plum, MindDay, Livi, HYROX, and Randox Health for UK lab expansion. The company also hired Dr. Julien Do Vale as Chief Medical Officer to scale clinical operations.